Safety and Efficacy of Abatacept in IgG4-Related Disease
Status:
Completed
Trial end date:
2020-11-10
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single center, proof of concept clinical trial in subjects with active
IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be
enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept
(125mg) for 24 doses (24 weeks).